A nasal powder for hypoglycemia, new cancer biosimilar & 2 more recent FDA approvals

Four drugs or medical devices approved by the FDA since July 19:

1. Baqsimi is a nasal powder for severe hypoglycemia, which occurs when a patient's blood sugar falls to a dangerously low level. It usually happens in people who have diabetes. It is the first emergency treatment that can be administered without an injection. 

2. Hadlima is a biosimilar to AbbVie's blockbuster rheumatoid arthritis treatment Humira. It won't be available in the U.S. until June 2023.

3. Ruxience is a biosimilar to Rituxan, a treatment for Non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.  

4. The FDA has approved several new generics of Lyrica, a brand-name drug manufactured by Pfizer to treat fibromyalgia, nerve pain and partial onset seizures in patients 17 years of age and older. They are the first FDA-approved generics for the drug, pregabalin.

More articles on pharmacy:
9 recent drug, device recalls
Owens Healthcare to sell 12 retail pharmacies to CVS
The pharmacies that received the most opioids in every state

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months